slideshow 1

Acpharis Awarded SBIR for Development of Covalent Fragments

Covalent drugs represent a significant portion of current pharmaceuticals, with the top 26 having sales of over $30B in the US alone. While in the past target-directed drug discovery projects rarely pursued covalent binders due to safety concerns, the industry is increasingly investing in the use of targeted covalent inhibitors (TCIs) that utilize soft reactive warheads, weak electrophiles that become locally reactive only in the context of the topology of a binding site.

Istvan Enyedy to Speak About Atlas at Drug Discovery Chemistry Conference

Acpharis's collaborator Istvan Enyedy will present a talk on "The Use of Solvent Mapping for Improving Docking and Scoring" in the Kinase Inhibitor track of the Drug Discovery Chemistry conference in San Diego on April 24. Istvan has done exciting work on combining the results of solvent mapping with the use of docking software from OpenEye.

Istvan's abstract is reproduced below:

Encounter Complexes in Protein-Protein Association

Acpharis's scientists published an exciting paper in eLife today on using Acpharis's protein-protein docking program, Piper, to model encounter complexes in protein-protein association. While crystal structures provide a static image of proteins interacting, which can be useful in optimizing biologics design, understanding the association pathway to this complex is equally important for obtaining a full picture of the physical basis of complex formation.